Your browser doesn't support javascript.
loading
Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein.
Oyen, David; Torres, Jonathan L; Aoto, Phillip C; Flores-Garcia, Yevel; Binter, Spela; Pholcharee, Tossapol; Carroll, Sean; Reponen, Sini; Wash, Rachael; Liang, Qi; Lemiale, Franck; Locke, Emily; Bradley, Allan; King, C Richter; Emerling, Daniel; Kellam, Paul; Zavala, Fidel; Ward, Andrew B; Wilson, Ian A.
Afiliación
  • Oyen D; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Torres JL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Aoto PC; Department of Pharmacology, University of California at San Diego, La Jolla, California, United States of America.
  • Flores-Garcia Y; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Binter S; Kymab Ltd., The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom.
  • Pholcharee T; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Carroll S; Atreca Inc., South San Francisco, California, United States of America.
  • Reponen S; Atreca Inc., South San Francisco, California, United States of America.
  • Wash R; Kymab Ltd., The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom.
  • Liang Q; Kymab Ltd., The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom.
  • Lemiale F; PATH's Malaria Vaccine Initiative, PATH Center for Vaccine Innovation and Access, Washington, United States of America.
  • Locke E; PATH's Malaria Vaccine Initiative, PATH Center for Vaccine Innovation and Access, Washington, United States of America.
  • Bradley A; Kymab Ltd., The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom.
  • King CR; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.
  • Emerling D; PATH's Malaria Vaccine Initiative, PATH Center for Vaccine Innovation and Access, Washington, United States of America.
  • Kellam P; Atreca Inc., South San Francisco, California, United States of America.
  • Zavala F; Kymab Ltd., The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom.
  • Ward AB; Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Wilson IA; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
PLoS Pathog ; 16(3): e1008373, 2020 03.
Article en En | MEDLINE | ID: mdl-32150583
ABSTRACT
Lasting protection has long been a goal for malaria vaccines. The major surface antigen on Plasmodium falciparum sporozoites, the circumsporozoite protein (PfCSP), has been an attractive target for vaccine development and most protective antibodies studied to date interact with the central NANP repeat region of PfCSP. However, it remains unclear what structural and functional characteristics correlate with better protection by one antibody over another. Binding to the junctional region between the N-terminal domain and central NANP repeats has been proposed to result in superior protection this region initiates with the only NPDP sequence followed immediately by NANP. Here, we isolated antibodies in Kymab mice immunized with full-length recombinant PfCSP and two protective antibodies were selected for further study with reactivity against the junctional region. X-ray and EM structures of two monoclonal antibodies, mAb667 and mAb668, shed light on their differential affinity and specificity for the junctional region. Importantly, these antibodies also bind to the NANP repeat region with equal or better affinity. A comparison with an NANP-only binding antibody (mAb317) revealed roughly similar but statistically distinct levels of protection against sporozoite challenge in mouse liver burden models, suggesting that junctional antibody protection might relate to the ability to also cross-react with the NANP repeat region. Our findings indicate that additional efforts are necessary to isolate a true junctional antibody with no or much reduced affinity to the NANP region to elucidate the role of the junctional epitope in protection.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Plasmodium falciparum / Sitios de Unión de Anticuerpos / Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Anticuerpos Monoclonales de Origen Murino / Epítopos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS Pathog Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Plasmodium falciparum / Sitios de Unión de Anticuerpos / Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Anticuerpos Monoclonales de Origen Murino / Epítopos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS Pathog Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos